ReviewMolecular biology reports2026
Targeting Campylobacter infection using nano-azurin: innate immune reprogramming and anticancer implications.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nano-azurin is redox-active protein has recently attracted attention as potential multifunctional therapeutics, primarily in infectious disease and cancer. This review highlights its potential against Campylobacter spp., including antibiotic resistant variants, in addition to anticancer properties. Campylobacteriosis is a serious public health problem worldwide because of its zoonotic potential and the increasing antimicrobial resistance (AMR) rates as well as its relationship with gastrointestinal carcinogenesis. Nano-azurin not only affects microbial viability and biofilm formation, but also stimulates host immune responses. In cancer settings, it specifically binds to neoplastic cells inducing apoptosis and preventing tumor growth. In particular, a nanoformulation can enhance the stability of the drug, its bioavailability and its selective delivery by lowering systemic toxicity. Moreover, nano-azurin regulates innate immunity functions contributing to the elimination of pathogens and the immune surveillance of tumours. The dual-action profile is promising, though several obstacles with respect to large-scale manufacturing, pharmacokinetics behaviours and clinical translation are important. In summary, nano-azurin is a new nanobiotherapeutic platform at the cross between antimicrobial therapy and cancer immunotherapy, which shows great promise for treatment of malignancies related to infections.
Indexed as
Identifiers
42417955What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.